DCIS genomic signatures define biology and clinical outcome: Human Tumor Atlas Network (HTAN) analysis of TBCRC 038 and RAHBT cohorts
暂无分享,去创建一个
Kathleen E. Houlahan | Tyler T. Risom | R. Tibshirani | G. Colditz | D. Ding | K. Owzar | Jingqin Luo | K. Deschryver | K. Polyak | Lorraine M. King | C. Maley | C. Curtis | G. Gupta | A. DeMichele | Shirley X. Zhu | Jason K. Wang | A. Thompson | S. Varma | Robert West | T. King | J. Seoane | P. Mcauliffe | Shiqin Wei | Shu Jiang | A. Storniolo | M. Matusiak | M. Kilgore | Dadong Zhang | F. Couch | S. Strand | K. Gallagher | Chunfang Zhu | E. Shelley Hwang | Lauren Anderson | Luis H. Cisneros | Bryan E. Harmon | A. Hall | Aziz Khan | D. Veis | J. Nangia | Sucheta A. Srivastava | P. McAuliffe | Joanna S. Lee | J. Tappenden | J. Tseng | J. Marks | S. Vennam | Belén Rivero-Gutiérrez | L. Simpson | T. Hardman | Robyn Burns | C. Straub | R. M. Angelo | Jingqin R Luo | Bryan Harmon | Siri H. Strand
[1] P. Kristel,et al. Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ , 2021, medRxiv.
[2] K. Chin,et al. Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System , 2020, Molecular Cancer Research.
[3] Tonje G. Lien,et al. Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions , 2020, npj Breast Cancer.
[4] K. Polyak,et al. Immune Escape during Breast Tumor Progression , 2020, Cancer Immunology Research.
[5] J. Reis-Filho,et al. Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma , 2020, Clinical Cancer Research.
[6] Yul Ri Chung,et al. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast , 2020, Breast Cancer Research.
[7] S. Killcoyne,et al. Genomic copy number predicts esophageal cancer years before transformation , 2020, bioRxiv.
[8] Yuan Wang,et al. Single-Cell Map of Diverse Immune Phenotypes in the Metastatic Brain Tumor Microenvironment of Non Small Cell Lung Cancer , 2019, bioRxiv.
[9] Nicholas J. Wang,et al. Genomic landscape of ductal carcinoma in situ and association with progression , 2019, Breast Cancer Research and Treatment.
[10] Ruud H. Brakenhoff,et al. ACE: absolute copy number estimation from low-coverage whole-genome sequencing data , 2019, Bioinform..
[11] L. Shevde,et al. The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.
[12] Bin Liu,et al. Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups , 2019, Nature.
[13] S. Srivastava,et al. HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells. , 2019, Cancer letters.
[14] J. Jonkers,et al. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment , 2018, Cancer and Metastasis Reviews.
[15] Arnoldo Frigessi,et al. A Bayesian Two-Way Latent Structure Model for Genomic Data Integration Reveals Few Pan-Genomic Cluster Subtypes in a Breast Cancer Cohort , 2018, bioRxiv.
[16] Ambrose J. Carr,et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.
[17] Jesper Eisfeldt,et al. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants , 2018, bioRxiv.
[18] Adrian V. Lee,et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.
[19] Phuong Dao,et al. Single-cell Map of Diverse Immune Phenotypes Driven by the Tumor Microenvironment , 2018 .
[20] Mary E. Edgerton,et al. Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing , 2018, Cell.
[21] R. West,et al. Gene expression profiling of single cells from archival tissue with laser-capture microdissection and Smart-3SEQ , 2017, Genome Research.
[22] T. Sørlie,et al. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. , 2017, Cancer discovery.
[23] G. Parmigiani,et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer , 2017, Nature Communications.
[24] K. Yoon-Flannery,et al. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer , 2017, Annals of Surgical Oncology.
[25] Jianxin Wang,et al. BPG: Seamless, automated and interactive visualization of scientific data , 2019, BMC Bioinformatics.
[26] Kylie L. Gorringe,et al. Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features , 2017, Clinical Cancer Research.
[27] Francesca Martella,et al. Impact of hormonal status on outcome of ductal carcinoma in situ treated with breast-conserving surgery plus radiotherapy: Long-term experience from two large-institutional series. , 2017, Breast.
[28] L. Villani,et al. The Relationships between HER2 Overexpression and DCIS Characteristics , 2017, The breast journal.
[29] E. Rutgers,et al. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). , 2017, Breast.
[30] R. Kalluri. The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.
[31] T. Sørlie,et al. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. , 2016, Cell reports.
[32] Joel S. Parker,et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..
[33] L. Esserman,et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast , 2016, Breast Cancer Research and Treatment.
[34] Jaime Rodriguez-Canales,et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition , 2015, Clinical Cancer Research.
[35] A. Sahin,et al. A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. , 2015, Cancer research.
[36] Kylie L. Gorringe,et al. Copy number analysis of ductal carcinoma in situ with and without recurrence , 2015, Modern Pathology.
[37] Piet Demeester,et al. FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[38] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[39] E. Batlle,et al. TGF-beta in CAF-mediated tumor growth and metastasis. , 2014, Seminars in cancer biology.
[40] M. Reginato,et al. The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance* , 2013, The Journal of Biological Chemistry.
[41] Serafim Batzoglou,et al. Genome evolution during progression to breast cancer , 2013, Genome research.
[42] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[43] A. Schäffer,et al. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. , 2012, The American journal of pathology.
[44] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[45] Ian G. Campbell,et al. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma , 2012, Hereditary Cancer in Clinical Practice.
[46] David Venet,et al. Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..
[47] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[48] D. Allred,et al. Ductal carcinoma in situ: terminology, classification, and natural history. , 2010, Journal of the National Cancer Institute. Monographs.
[49] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[50] A. Krasnitz,et al. Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients , 2010, Science Translational Medicine.
[51] Karla Kerlikowske,et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.
[52] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[53] J. Thiery,et al. Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.
[54] A. Vincent-Salomon,et al. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues , 2007, Journal of Clinical Pathology.
[55] Wessel N. van Wieringen,et al. CGHcall: calling aberrations for array CGH tumor profiles , 2007, Bioinform..
[56] M. Hussein,et al. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations , 2006, Journal of Clinical Pathology.
[57] Jun Yao,et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. , 2006, Cancer research.
[58] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[59] S. Devries,et al. Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In situ , 2004, Clinical Cancer Research.
[60] Rameen Beroukhim,et al. Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.
[61] T. Hagemann,et al. A Role for Endothelin-2 and Its Receptors in Breast Tumor Cell Invasion , 2004, Cancer Research.
[62] Pablo Tamayo,et al. Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[63] R. Salunga,et al. Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[64] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[65] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.